CTRI/2010/091/003064已完成2 期
A Randomized, Double-Blind, Placebo Controlled Study to Assess Safety and Tolerability of RotaVac Vaccine (Live Attenuated Bovine-Human (UK) Reassortant Pentavalent Rotavirus Vaccine)
Serum Institute of India Ltd0 个研究点目标入组 60 人开始时间: 待定最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Healthy male or female infant 8-10 weeks of age at the time of first dose of vaccination and born after 37 weeks of gestation and birth weight of 2500g
- •Written informed consent is obtained from the parent or legal guardian of the subject after nature of the study has been explained
- •Subject along with their parent or legal guardian will be available for the follow-up throughout the study period.
- •Access to telephone at home or in the immediate neighbourhood.
- •Free of obvious health problems as established by medical history, clinical examination and laboratory tests before entering into the study
- •The subjects will receive other childhood vaccines such as DTP, OPV, Hepatitis B vaccine, Haemophilus influenzae type b (Hib), BCG with at least 7 days separation from the first and subsequent dose of the study vaccine.
排除标准
- •Subjects participating in any other clinical trial.
- •Prior receipt of any rotavirus vaccine
- •Fever at time of immunization.
- •History of diarrhoea or blood in stool or abnormal stool pattern in past one week.
- •A known sensitivity or allergy to any components of the study medication.
- •History of chronic gastrointestinal disease, intussusceptions, gastrointestinal malformation or abdominal surgery.
- •Presence of any significant systemic disorder (cardiovascular, pulmonary, hepatic, renal, gastrointestinal, endocrine, immunological, dermatological, neurological, cancer or autoimmune disease) which would endanger the subject?s health or is likely to result in non conformance to the protocol.
- •Major congenital or genetic defect.
- •Has received immunosuppressant for more than 14 days or other immune-modifying drugs prior to the first vaccine dose.
- •Any confirmed or suspected immunosuppressive or immunodeficient condition, including human immunodeficiency virus (HIV) infection based on medical history and physical examination (no laboratory testing is required).
- •Household contact with an immunosuppressed individual or pregnant woman.
- •Has received any immunoglobulin therapy and/or blood products since birth or planned administration during the study period.
- •Subject is not suitable for inclusion in the study in the opinion of the investigator.
- •Investigator site personnel directly affiliated with this study and their immediate families. Immediate family is defined as a spouse, parent, child or sibling, whether biological or legally adopted.
- •Use of any investigational or non-registered drug other than the study vaccine(s) within 30 days preceding the first dose of the study vaccine or placebo, or planned use during the study period.
研究者
相似试验
进行中（未招募）
1 期
A study in which the safety and efficacy of Nefecon is compared with placebo in patients with primary IgA Nephropathy.Primary IgA nephropathy patients at risk of developing end stage renal diseaseMedDRA version: 20.0Level: LLTClassification code 10069341Term: Berger's diseaseSystem Organ Class: 100000004857EUCTR2017-004902-16-FICalliditas Therapeutics AB360
已完成
1 期
Clinical trial on rotavirus vaccine designed to check the safety and tolerability of the vaccines in healthy adults who will receive either study vaccine or similar looking vaccineCTRI/2009/091/000821Serum Institute of India Pune India114
进行中（未招募）
1 期
A Study of Venetoclax Co-Administered with Low Dose Cytarabine Versus Low Dose Cytarabine in Untreated Patients with Acute Myeloid Leukemia Who Are Ineligible for Intensive ChemotherapyAcute Myeloid LeukemiaEUCTR2016-003900-30-ESAbbVie Deutschland GmbH & Co. KG175
进行中（未招募）
1 期
A study in which the safety and efficacy of Nefecon is compared with placebo in patients with primary IgA Nephropathy.Primary IgA nephropathy patients at risk of developing end stage renal diseaseMedDRA version: 20.0Level: LLTClassification code 10069341Term: Berger's diseaseSystem Organ Class: 100000004857EUCTR2017-004902-16-ESCalliditas Therapeutics AB450
进行中（未招募）
1 期
Study of COR388 in Subjects with Alzheimer’s DiseaseAlzheimer’s DiseaseMedDRA version: 20.0Level: LLTClassification code 10001896Term: Alzheimer's diseaseSystem Organ Class: 100000004852EUCTR2019-000370-27-GBCortexyme, Inc.573